CD320 Antibody

What is CD320 and why is it important in biomedical research?

CD320, also known as 8D6, VLDL, 8D6A, TCBLR, or TCN2R, is a single-pass type I membrane protein containing two LDL-receptor class A domains . It functions as the receptor for cellular uptake of transcobalamin-bound cobalamin (vitamin B12), making it essential for normal cellular metabolism . CD320 is abundantly expressed on follicular dendritic cells (FDCs) and has been shown to enhance proliferation of germinal center B cells . Its critical role in vitamin B12 transport, particularly across the blood-brain barrier, has recently positioned it as an important target in neurological research. When designing experiments involving CD320, researchers should consider its expression patterns across different tissues and cell types, as well as its potential interactions with other proteins in the vitamin B12 metabolism pathway.

What are the structural characteristics of CD320 protein that affect antibody selection?

CD320 has a calculated molecular mass of 29 kDa, though the observed molecular weight in experimental conditions typically ranges from 35-40 kDa and 60-70 kDa, likely due to post-translational modifications such as glycosylation . The protein contains two conserved low-density lipoprotein receptor type A (LDLR-A) domains involved in ligand binding . When selecting antibodies, researchers should be aware that:

• The extracellular domain (Leu31-Val231) is commonly used as an immunogen for antibody production

• Epitope accessibility may vary depending on CD320's interaction with its ligand, transcobalamin

• The LDLR-A domains contain critical binding sites, including a potential DGSDE motif in the first domain that may affect protein localization

Crystallographic studies have revealed that CD320 interacts with transcobalamin through specific residues that can be blocked by certain antibodies, affecting vitamin B12 uptake . For optimal antibody selection, researchers should consider the specific domain or epitope they wish to target based on their experimental objectives.

What are the optimal protocols for using CD320 antibodies in immunohistochemistry?

For successful immunohistochemistry (IHC) with CD320 antibodies, the following methodological considerations are essential:

• Antigen retrieval: Evidence suggests using TE buffer at pH 9.0 yields optimal results, though citrate buffer at pH 6.0 may serve as an alternative .

• Dilution optimization: A typical starting dilution range is 1:200-1:800 for IHC applications, but this should be titrated for each specific antibody and tissue type .

• Tissue selection: Human tonsillitis tissue has been validated as a positive control for IHC applications .

• Detection systems: Both chromogenic and fluorescent detection methods have been successfully employed, with the latter offering advantages for co-localization studies.

For membrane protein visualization, methanol fixation (5 minutes at room temperature) followed by incubation with 5% BSA in PBS has shown effective results . When analyzing CD320 localization in polarized cell types, co-staining with membrane markers such as ZO-1 can help distinguish between apical and basolateral distributions .

How should researchers optimize Western blot protocols for detecting CD320?

Western blot detection of CD320 requires careful optimization due to its variable observed molecular weights:

• Sample preparation: For optimal detection, researchers should:

  • Use protein extraction buffers containing protease inhibitors to prevent degradation

  • Consider using deglycosylation enzymes to confirm glycosylation-related weight shifts

  • Include both reducing and non-reducing conditions to assess potential disulfide bonds

• Gel selection and transfer conditions:

  • 10-12% polyacrylamide gels are generally suitable

  • Semi-dry or wet transfer methods may be employed (transfer at 100V for 1 hour or 30V overnight)

  • PVDF membranes typically yield better results than nitrocellulose for CD320 detection

• Antibody dilution and detection:

  • Recommended dilution range: 1:500-1:3000

  • Primary antibody incubation: overnight at 4°C

  • Secondary antibody selection: HRP-conjugated anti-rabbit IgG works well with most commercial anti-CD320 antibodies

• Controls and verification:

  • Positive controls: HL-60 cells, K-562 cells, Raji cells, and human placenta tissue

  • Knockout/knockdown validation is essential for confirming specificity

When interpreting results, researchers should be aware that CD320 may appear at 35-40 kDa and/or 60-70 kDa bands, with variation depending on cell type and experimental conditions .

How can CD320 antibodies be utilized to investigate autoimmune central vitamin B12 deficiency?

Recent research has identified autoantibodies targeting CD320 in patients with neurological symptoms despite normal serum B12 levels . For investigating autoimmune central vitamin B12 deficiency (ABCD), researchers can employ the following methodological approaches:

• Detection of anti-CD320 autoantibodies:

  • Programmable phage immunoprecipitation sequencing (PhIP-seq) has successfully identified anti-CD320 autoantibodies

  • Cell-based assays using CD320-overexpressing HEK293T cells can confirm autoantibody binding

  • Western blot analysis of patient serum against recombinant CD320 protein provides a complementary approach

• Functional assessment of autoantibody impact:

  • Holotranscobalamin uptake assays in cell lines (e.g., HEK293T) treated with patient CSF/serum can quantify inhibitory effects

  • Immunoglobulin depletion from patient samples serves as a critical control to confirm antibody-mediated effects

  • CD320 knockout cells provide negative controls for specificity validation

• Clinical correlation methods:

  • Paired analysis of serum and CSF B12 levels (ratio typically 0.02 in healthy controls)

  • Measurement of methylmalonic acid (MMA) in CSF as a metabolic marker of B12 deficiency

  • Correlation of antibody titers with neurological symptoms and response to treatment

Research indicates that detection of anti-CD320 in serum is 36% sensitive and 96% specific for a low CSF to serum holotranscobalamin ratio, with anti-CD320 seropositivity predicting elevated CSF MMA with 78% positive predictive value .

What methodologies are available for studying CD320 variants and their functional consequences?

Several approaches have been developed to investigate CD320 variants such as p.E88del, which affects cobalamin uptake :

• Cell-based functional assays:

  • Radiolabeled holotranscobalamin binding and uptake assays comparing wild-type and variant CD320

  • Measurement of cobalamin coenzyme derivatives (adenosylcobalamin and methylcobalamin) synthesis

  • Assessment of cobalamin-dependent enzyme activities (methylmalonyl-CoA mutase and methionine synthase)

• Protein localization studies:

  • Transfection of polarized cell models (e.g., MDCK cells) with Flag-tagged CD320 variants

  • Immunostaining with anti-Flag antibodies and membrane markers (e.g., ZO-1)

  • Confocal microscopy analysis of apical versus basolateral distribution

  • Quantification using fluorescence intensity ratios (F_BL/F_Total)

• Structural analysis methods:

  • X-ray crystallography of wild-type and variant CD320 in complex with transcobalamin

  • Thermostability assays to assess complex stability

  • Solid-phase binding assays using immobilized MBP-tagged, biotinylated CD320 to determine affinity constants

These methodologies have revealed that the CD320 p.E88del variant demonstrates reduced binding of radiolabeled holotranscobalamin and decreased cellular uptake of cobalamin, accompanied by reduced synthesis of cobalamin coenzyme derivatives and decreased function of cobalamin-dependent enzymes .

How can researchers validate CD320 antibody specificity?

Rigorous validation of CD320 antibody specificity is crucial for reliable experimental results. The following methodological approaches are recommended:

• Genetic knockout/knockdown controls:

  • CRISPR-Cas9 mediated knockout of CD320 in cell lines provides the most stringent negative control

  • siRNA knockdown can serve as an alternative approach

  • Both Western blot and immunostaining should show significant signal reduction in knockout/knockdown samples

• Epitope blocking experiments:

  • Pre-incubation of antibodies with immunizing peptides should abolish specific signals

  • Sequential alanine mutagenesis of critical epitopes can define the binding region with precision

• Recombinant protein controls:

  • Overexpression of CD320 in cell lines should result in increased signal intensity

  • Testing across multiple applications (WB, IHC, IF) provides comprehensive validation

  • Cross-reactivity testing with related proteins helps confirm specificity

• Species cross-reactivity assessment:

  • Test antibodies across human, mouse, and rat samples if cross-reactivity is claimed

  • Be aware that some antibodies may be species-specific (human-only vs. multi-species reactive)

Published literature utilizing CD320 antibodies, particularly those with knockout validations, can provide valuable reference points for anticipated staining patterns and molecular weights.

What are common pitfalls in CD320 antibody-based experiments and how can they be addressed?

Researchers working with CD320 antibodies should be aware of several common challenges:

• Variable molecular weight detection:

  • CD320 may appear at different molecular weights (29 kDa calculated, but 35-40 kDa and 60-70 kDa observed)

  • Solution: Include positive control lysates with known CD320 expression and consider deglycosylation experiments

• Background signal in immunostaining:

  • Non-specific binding can occur, particularly in tissues with high lipid content

  • Solution: Optimize blocking conditions (5% BSA recommended), include knockout controls, and titrate antibody concentrations carefully

• Epitope masking during protein interactions:

  • CD320-transcobalamin interaction may mask certain epitopes

  • Solution: Test multiple antibodies targeting different regions of CD320 or consider mild fixation conditions that preserve epitope accessibility

• pH-dependent binding effects:

  • Studies show significantly reduced affinity of transcobalamin for CD320 at low pH, which may affect experimental outcomes

  • Solution: Carefully control buffer pH in binding studies and consider pH as a variable in endocytosis experiments

• Cross-reactivity with related LDLR family proteins:

  • CD320 shares structural features with other LDLR family members

  • Solution: Include specific controls and consider domain-specific antibodies for distinguishing between family members

How are CD320 antibodies being used to investigate alternative B12 uptake pathways?

Recent research has uncovered alternative pathways for vitamin B12 uptake that may explain tissue-specific effects of CD320 dysfunction:

• Genome-wide CRISPR screening approaches:

  • CRISPR-Cas9 knockout libraries have identified LDLR as an alternative B12 uptake pathway outside the CNS

  • Methodologically, this involves:

    • Creating genome-wide knockout cell libraries

    • Selecting for cells with retained B12 uptake despite CD320 deficiency

    • Sequencing enriched sgRNAs to identify candidate genes

    • Validating hits with individual knockouts and rescue experiments

• Tissue-specific pathway analysis:

  • Comparison of B12 uptake mechanisms between neural and hematopoietic cells

  • Methods include:

    • Primary cell isolation from different tissues

    • Measurement of B12 uptake in the presence of CD320 inhibition

    • Transcriptomic profiling to identify differentially expressed receptors

    • Targeted inhibition of candidate pathways

• In vivo models for pathway validation:

  • CD320 knockout animal models can reveal compensatory mechanisms

  • Tissue-specific conditional knockouts help dissect the relative importance of different uptake pathways

  • Combined inhibition of multiple pathways can establish their functional redundancy

This research direction is particularly relevant for understanding why anti-CD320 autoantibodies cause neurological symptoms while sparing hematological manifestations of B12 deficiency .

What are the latest methods for therapeutic targeting of CD320-associated disorders?

Emerging therapeutic approaches targeting CD320-associated disorders include:

• Immunomodulatory strategies for autoimmune B12 deficiency:

  • Clinical evidence suggests immunosuppressive treatment combined with high-dose B12 supplementation improves CSF B12 levels and neurological symptoms

  • Methodological considerations include:

    • Monitoring of both serum and CSF B12 levels before and after treatment

    • Assessment of autoantibody titers in response to therapy

    • Correlation of biochemical parameters with clinical improvements

• Single B-cell isolation and monoclonal antibody characterization:

  • Advanced techniques like the Beacon optofluidic system enable isolation of anti-CD320 antibody-producing B cells from patient samples

  • This approach allows:

    • Identification of expanded B cell clones (indicating autoimmune response)

    • Sequencing and recombinant expression of patient-derived antibodies

    • Functional characterization of monoclonal antibodies in vitro and in BBB models

• Targeted CD320 overexpression or stabilization:

  • Gene therapy approaches to increase CD320 expression could potentially overcome autoantibody-mediated internalization

  • Development of small molecule compounds that stabilize CD320 at the cell surface despite autoantibody binding

• High-dose B12 supplementation protocols:

  • Evidence suggests that high-dose systemic B12 supplementation can partially overcome CD320 autoantibody-mediated blockade

  • Methodological research is needed to optimize:

    • Dosing regimens for various clinical presentations

    • Routes of administration (oral vs. parenteral)

    • Monitoring protocols for treatment efficacy

What factors should researchers consider when selecting CD320 antibodies for different applications?

Selecting the appropriate CD320 antibody requires consideration of several key factors:

• Application-specific requirements:

• Species reactivity requirements:

  • Determine whether human-specific or cross-reactive antibodies are needed

  • Verify species reactivity claims with experimental validation

  • Consider evolutionary conservation of the targeted epitope

• Monoclonal vs. polyclonal selection:

  • Monoclonal: Higher specificity, consistent lot-to-lot reproducibility

  • Polyclonal: Multiple epitope recognition, potentially stronger signal

  • Match antibody type to experimental needs (e.g., monoclonals for precise epitope mapping)

• Validated positive controls:

  • HL-60 cells, K-562 cells, Raji cells, and human placenta tissue serve as reliable positive controls

  • Consider tissue-specific expression patterns when selecting controls

How do researchers optimize CD320 antibody use for detecting autoantibodies in clinical samples?

Detecting anti-CD320 autoantibodies in patient samples requires specialized methodological approaches:

• Cell-based assays:

  • Transfection of HEK293T cells with CD320 expression constructs

  • Incubation with patient serum or CSF (typically 1:100-1:500 dilution)

  • Detection with fluorescently-labeled secondary antibodies against human IgG

  • Analysis by flow cytometry or fluorescence microscopy

  • Include CD320-negative cells as essential controls

• Solid-phase immunoassays:

  • ELISA using recombinant CD320 protein or synthetic peptides covering key epitopes

  • Western blot against recombinant CD320 protein

  • Dot blot assays for rapid screening

  • Implementation of appropriate cut-offs based on healthy control samples

• Functional assays to confirm pathogenicity:

  • Holotranscobalamin uptake inhibition assays

  • Complement-dependent cytotoxicity testing

  • Antibody-dependent cellular cytotoxicity assessment

  • Blood-brain barrier model systems to evaluate B12 transport inhibition

• Sample handling considerations:

  • Paired serum and CSF collection when possible

  • Standardized processing protocols (centrifugation, storage temperature)

  • Inclusion of protease inhibitors to prevent antibody degradation

  • Assessment of multiple timepoints when monitoring treatment response

Research indicates that detection of anti-CD320 in the serum is 36% sensitive and 96% specific for a low CSF to serum holotranscobalamin ratio, making it a potentially valuable diagnostic marker .